Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
63
Language
English
Published on
30/10/24
You may also be interested by these reports :
09/12/25
In addition to our estimates being revised lower, we have applied a 10% discount to peer-based valuation metrics to reflect the delayed recovery in ...
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...
05/12/25
On the back of promising operating results, which also prompted management to upgrade its guidance, our estimates reset higher. This is commendable, ...
05/12/25
We have incorporated the actual figures for the FY24/25 ending in June 2025. While the recurring EBIT was in line with our forecast (€44.2m vs ...